{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T05:19:30Z","timestamp":1763356770602,"version":"3.45.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The treatment landscape of chronic myeloid leukemia (CML) has evolved with the introduction of second- and third-generation tyrosine kinase inhibitors (TKIs), oCering potential advantages over imatinib. We analyzed prescription trends and public awareness of TKIs to assess the adoption of newer agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Monthly US prescription data from the IQVIA National Prescription Audit (NPA) and Google Trends search volumes from March 1, 2017, to November 31, 2024, were analyzed for visual and quantitative trends and correlation patterns. Studied TKIs included imatinib (first generation), dasatinib, bosutinib, nilotinib (second generation), and ponatinib, asciminib (third generation).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Second-generation TKIs increased by 14.4% (15,171 to 17,363 average monthly prescriptions) between 2017 and 2024, while the use of imatinib declined (-10.0%, from 18,704 to 16,835). Bosutinib (+144.1%) and dasatinib (+27.8%) usage increased during this period, while nilotinib prescriptions decreased (-26.0%). Third-generation TKIs saw substantial growth (696 to 2,123 average monthly prescriptions), led by ponatinib (+86.6%) and asciminib (+235.0% since 2022). Online search volumes strongly correlated with prescription trends, particularly for newer TKIs: asciminib (r = 0.85), bosutinib (r = 0.74), nilotinib (r = 0.74), ponatinib (r = 0.63), and dasatinib (r = 0.51). Imatinib showed little correlation (r = 0.21). Prescription patterns varied across disciplines, with Advanced Practice Providers (APPs) prescribing imatinib 9% less frequently than internists\/primary care physicians (PCPs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>These data highlight a shift toward newer TKIs in CML treatment, mirroring guideline recommendations and rising public awareness. Online search trends complement traditional prescription monitoring, oCering near real-time insights into evolving prescribing practices and drug adoption.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1711453","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T05:16:59Z","timestamp":1763356619000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal analysis of usage and public awareness of tyrosine kinase inhibitors for CML"],"prefix":"10.3389","volume":"15","author":[{"given":"Adrian E.","family":"Schroer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiffany","family":"Javadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ankit","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Furkan","family":"Torlak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Joseph R.","family":"McFarland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Girish","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre L.","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamaal","family":"Benjamin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moaz M.","family":"Choudhary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akram","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"le Coutre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Blaha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Berning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Dzaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S382090","article-title":"Chronic myeloid leukemia, from pathophysiology to treatment-free remission: A narrative literature review","volume":"14","author":"Rinaldi","year":"2023","journal-title":"J Blood Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2325-z","article-title":"Natural course and biology of CML","author":"Chereda","year":"2015","journal-title":"Ann Hematol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.6004\/jnccn.2024.0007","article-title":"Chronic myeloid leukemia, version 2.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Shah","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0842-9","article-title":"Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-358135","article-title":"Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2022000328","article-title":"Management of TKI-resistant chronic phase CML","volume":"2022","author":"Hughes","year":"2022","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2013.05.022","article-title":"Efficacy of ponatinib against ABL tyrosine kinase inhibitor-resistant leukemia cells","volume":"435","author":"Okabe","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure","volume":"381","author":"Hughes","year":"2019","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/cancers13194820","article-title":"Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia-from molecular mechanisms to clinical relevance","volume":"13","author":"Alves","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2019.01.001","article-title":"Google Trends: Opportunities and limitations in health and health policy research","volume":"123","author":"Arora","year":"2019","journal-title":"Health Policy"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2196\/13439","article-title":"Google trends in infodemiology and infoveillance: methodology framework","volume":"5","author":"Mavragani","year":"2019","journal-title":"JMIR Public Health Surveill"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/ijerph191912394","article-title":"Forecasting and surveillance of COVID-19 spread using google trends: literature review","volume":"19","author":"Saegner","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1515373112","article-title":"Accurate estimation of influenza epidemics using Google search data via ARGO","volume":"112","author":"Yang","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1324095","article-title":"Online searches for hepatocellular carcinoma drugs mirror prescription trends across specialties and changes in guideline recommendations","volume":"14","author":"Berning","year":"2024","journal-title":"Front Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.936651","article-title":"Online searches for SGLT-2 inhibitors and GLP-1 receptor agonists correlate with prescription rates in the United States: An infodemiological study","volume":"9","author":"Dzaye","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2196\/20426","article-title":"Google trends insights into reduced acute coronary syndrome admissions during the COVID-19 pandemic: infodemiology study","volume":"4","author":"Senecal","year":"2020","journal-title":"JMIR Cardio"},{"key":"B18","doi-asserted-by":"publisher","first-page":"20552076211033420","DOI":"10.1177\/20552076211033420","article-title":"Increasing utility of Google Trends in monitoring cardiovascular disease","volume":"7","author":"Senecal","year":"2021","journal-title":"Digit Health"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2097","article-title":"Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012","volume":"37","author":"Turner","year":"2014","journal-title":"Diabetes Care"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.023811","article-title":"National trends in use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists by cardiologists and other specialties, 2015 to 2020","volume":"11","author":"Adhikari","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"B21","volume-title":"gtrendspy and gtrendR: Packages for analyzing Google Trends Data","author":"Caputi","year":"2020"},{"key":"B22","unstructured":"FDA approves asciminib for Philadelphia chromosome-positive chronic myeloid leukemia"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01589-y","article-title":"Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial","volume":"36","author":"Brummendorf","year":"2022","journal-title":"Leukemia"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001329","article-title":"First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis","volume":"4","author":"Vener","year":"2020","journal-title":"Blood Adv"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0071","article-title":"Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology","volume":"16","author":"Radich","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.59","article-title":"Targeted therapy: Generic imatinib - impact on frontline and salvage therapy for CML","volume":"13","author":"Gorkin","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"B31","unstructured":"Nilotinib accord: European medicines agency\n          \n          \n          2024"},{"key":"B32","doi-asserted-by":"publisher","first-page":"44","DOI":"10.21037\/cco.2016.05.01","article-title":"The role of Advanced Practice Providers in interdisciplinary oncology care in the United States","volume":"5","author":"Reynolds","year":"2016","journal-title":"Chin Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1200\/JOP.091062","article-title":"Understanding the role of physician assistants in oncology","volume":"6","author":"Ross","year":"2010","journal-title":"J Oncol Pract"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1188\/18.ONF.786-800","article-title":"Understanding the role of advanced practice providers in oncology in the United States","volume":"9","author":"Bruinooge","year":"2018","journal-title":"J Adv Pract Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.57232","article-title":"Longitudinal analysis of obesity drug use and public awareness","volume":"8","author":"Berning","year":"2025","journal-title":"JAMA Netw Open"},{"key":"B36","unstructured":"Cancer stat facts: leukemia \u2014 Chronic myeloid leukemia (CML)"},{"key":"B37","unstructured":"Cancer stat facts: leukemia \u2014 Acute lymphocytic leukemia (ALL)"},{"key":"B38","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.annonc.2023.09.3112","article-title":"ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia","volume":"35","author":"Hoelzer","year":"2024","journal-title":"Ann Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-051912","article-title":"Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII\/Eastern Cooperative Oncology Group (ECOG) 2993 trial","volume":"109","author":"Moorman","year":"2007","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.4120","article-title":"Incidence of gastrointestinal stromal tumors in the United States from 2001-2015: A United States cancer statistics analysis of 50 states","volume":"11","author":"Patel","year":"2019","journal-title":"Cureus"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0058","article-title":"NCCN guidelines(R) insights: gastrointestinal stromal tumors, version 2.2022","volume":"20","author":"von Mehren","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"B42","unstructured":"NCCPA 2023 statistical profile of board certified PAs 2024 [03.21.2025]"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1711453\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T05:17:00Z","timestamp":1763356620000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1711453\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":42,"alternative-id":["10.3389\/fonc.2025.1711453"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1711453","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"article-number":"1711453"}}